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Running title  




Drugs of abuse induce widespread synaptic adaptations in the mesolimbic dopamine (DA) 
neurons. Such drug-induced neuroadaptations may constitute an initial cellular mechanism 
eventually leading to compulsive drug-seeking behavior. To evaluate the impact of GABAB 
receptors on addiction-related persistent neuroplasticity, we tested the ability of orthosteric 
agonist baclofen and two positive allosteric modulators (PAMs) of GABAB receptors to 
suppress neuroadaptations in the ventral tegmental area (VTA) and reward-related behaviors 
induced by ethanol and cocaine. A novel compound (S)-1-(5-fluoro-2,3-dihydro-1H-inden-2-
yl)-4-methyl-6,7,8,9-tetrahydro-[1,2,4]triazolo[4,3-a]quinazolin-5(4H)-one (ORM-27669) was 
found to be a GABAB PAM of low efficacy as agonist, whereas the reference compound 
(R,S)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one (rac-BHFF) had a 
different allosteric profile being a more potent PAM in the calcium-based assay and an 
agonist, coupled with potent PAM activity, in the [35S]GTPgS binding assay in rat and human 
recombinant receptors. Using autoradiography, the high-efficacy rac-BHFF and the low-
efficacy ORM-27669 potentiated the effects of baclofen on [35S]GTPgS binding with identical 
brain regional distribution. Treatment of mice with baclofen, rac-BHFF or ORM-27669 failed to 
induce glutamate receptor neuroplasticity in the VTA DA neurons. Pretreatment with rac-
BHFF at non-sedative doses effectively reversed both ethanol- and cocaine-induced plasticity 
and attenuated cocaine i.v. self-administration and ethanol drinking. Pretreatment with ORM-
27669 only reversed ethanol-induced neuroplasticity and attenuated ethanol drinking, but had 
no effects on cocaine-induced neuroplasticity or self-administration. These findings 
encourage further investigation of GABAB receptor PAMs with different efficacies in addiction 
models to develop novel treatment strategies for drug addiction. 
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Despite the drugs of abuse having different primary molecular targets in the brain, mesolimbic 
DA neurons in the ventral tegmental area (VTA) and the nucleus accumbens are thought to 
be their first common cellular targets (Kauer and Malenka, 2007). Indeed, drugs of abuse 
trigger long-term glutamate receptor neuroplasticity in VTA DA neurons, which in susceptible 
subjects might initiate neuroadaptations leading eventually to addiction (Korpi et al., 2015; 
Luthi and Luscher, 2014). Therefore, testing of anti-abuse agents for their efficacy against 
induction of neuroplasticity in the VTA DA neurons would give important information on their 
addiction or anti-addiction potential, when appropriately coupled to preclinical behavioral 
tests, such as drug self-administration and place conditioning. 
The GABAB receptor agonist baclofen is well-known to acutely suppress DA 
release induced by morphine, nicotine and cocaine (Fadda et al., 2003) and this property of 
GABAB receptor agonistic ligands has been proposed to be exploited in the treatment of 
dependence to multiple classes of abused substances (Filip et al., 2015). To date, baclofen is 
used off-label in the treatment of alcoholism in some countries, and in France it has been 
temporarily approved at high maximal doses (de Beaurepaire, 2014). At the cellular level, 
baclofen mediates neuronal inhibition by activating the metabotropic GABAB receptor, which 
activates Gi/o proteins leading to stimulation of K+-channels, inhibition of Ca2+-channels and to 
diverse downstream signaling pathways (Urwyler, 2011). In mesolimbic DA neurons 
expressing GABAB receptors (Bettler et al., 2004), baclofen reduces the firing rate and 
suppresses the burst firing and spontaneous pacemaker-like firing (Erhardt et al., 2002; 
Seutin et al., 1994), most likely via hyperpolarization induced by G protein-gated inwardly 
rectifying K+-channels (GIRK) (Cruz et al., 2004; Labouebe et al., 2007). At the behavioral 
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level, in several studies, baclofen has attenuated self-administration of several drugs of 
abuse, reinstatement of drug-seeking behavior and drug-induced conditioned place 
preference (CPP), drug-induced hyperlocomotion and locomotor sensitization, and withdrawal 
signs in animal models of drug dependence (Filip et al., 2015). Noteworthy, several anti-
addictive effects of baclofen have been detected after its injection directly into the VTA 
(Agabio and Colombo, 2015).  
In line with numerous animal studies [(Fattore et al., 2002) and references cited 
therein], high doses of baclofen were efficacious to completely suppress craving and sustain 
alcohol abstinence (Ameisen, 2005; de Beaurepaire, 2014; Muller et al., 2015). Also lower 
doses of baclofen have shown efficacy to reduce alcohol drinking in some studies (e.g. 
(Addolorato et al., 2011; Morley et al., 2014)), but not in others [e.g., (Beraha et al., 2016; 
Garbutt et al., 2010)]. Despite of its generally good tolerability and efficacy, patients with 
impaired renal function or with epilepsy or other seizure disorder history are at significant risk 
to accumulate baclofen to toxic levels (Agabio and Colombo, 2015). Furthermore, baclofen 
may induce profound sedation, muscle relaxation, memory impairment and sexual 
dysfunction (Agabio and Colombo, 2015). In alcohol abusers, pharmacokinetics of baclofen is 
highly variable, its brain penetration poor (which can prevent achieving efficacious exposure), 
and there is a possibility to develop tolerance and withdrawal syndrome (Marsot et al., 2014). 
Thus, there is a clear demand for new GABAB receptor compounds with a higher therapeutic 
index than what baclofen has. 
Positive allosteric modulators (PAMs) of GABAB receptors act at sites distinct 
from the orthosteric agonist binding site, at which baclofen acts (Urwyler, 2011). Because 
ideally PAMs are able to potentiate GABA responses only when and where it is endogenously 
released (Urwyler, 2011), they may provide a more physiologically relevant GABAB receptor 
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activation. Consequently, PAMs may have a different profile of adverse effects and be less 
harmful than full agonists (Koek et al., 2013). Indeed, in animal models new GABAB PAMs, 
rac-BHFF (Malherbe et al., 2008) and GS39783 (Urwyler et al., 2003), given alone, did not 
display any sedative, cognition-impairing or myorelaxant activities (Cryan et al., 2004), nor did 
they affect food- and sucrose-maintained responding at doses that attenuated alcohol or 
nicotine intake and reward (Maccioni et al., 2010; Paterson et al., 2008). 
While the acute effects of GABAB receptor activation on VTA DA neurons have 
been well-characterized (Cruz et al., 2004), the effects of GABAB receptor agonists and PAMs 
on long-term neuroadaptations in the VTA have not been studied. In the present study, we 
examined whether baclofen and two PAMs of GABAB receptors (1) induce long-term 
glutamate synapse adaptations in VTA DA neurons, (2) suppress ethanol- and cocaine-
induced neuroadaptations and (3) reverse addiction-related behaviors at non-sedative doses 
in mice. We used here rac-BHFF and a novel non-benzofuranone compound ORM-27669 
[(S)-1-(5-fluoro-2,3-dihydro-1H-inden-2-yl)-4-methyl-6,7,8,9-tetrahydro-[1,2,4]triazolo[4,3-
a]quinazolin-5(4H)-one; Fig. 1A] as GABAB PAMs.  
 
MATERIALS AND METHODS 
In vitro GABAB receptor pharmacology 
In vitro GABAB receptor agonism and PAM pharmacology was studied in CHO cell lines 
stably expressing human or rat GABAB1A and GABAB2 receptor subunits co-transfected with 
Gα16 by using intracellular Ca2+ mobilization monitored by FLIPR Tetra system (Molecular 
Devices, CA, USA) and [35S]GTPgS binding assay, modified from (Malherbe et al., 2008). 
Potentiation of dose-responses of GABA and baclofen was studied as a leftward shift in the 
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presence of a 10-µM concentration of test compound. PAM EC50 values were determined 
using a dose-response of test compound in the presence of low concentrations (EC5 –EC11) 
of agonists. For detailed information, see Supporting Information Methods.  
 
Animals and in vivo manipulations 
We used juvenile (22-30 days old) male and female transgenic TH-EGFP mice (Gong et al., 
2003) for electrophysiology and adult (8-11 weeks old) male C57BL/6JCrl mice (Charles River 
Germany, Sulzfield) for ligand autoradiography and behavioral studies. All drug injections 
(intraperitoneal i.p., intravenous i.v., or intragastric i.g.) and behavioral tests were performed 
between 08:00 and 19:00 h when the lights were on, except the ethanol drinking study which 
was performed during the dark phase. All animal procedures were approved by the Southern 
Finland Provincial Government, and conducted according to the following guidelines: Act on 
Use of Animals for Experimental Purposes 497/2013; Decree on Use of Animals for 
Experimental Purposes 564/2013; and Directive 2010/63/EU of the European Parliament and 
of the Council of 22 September 2010 on the protection of animals used for scientific purpose.  
 
Agonist-stimulated [35S]GTPgS autoradiography 
The [35S]GTPgS autoradiography was performed in 14-µm coronal cryosections of mouse 
brains as previously described in detail (Korpi et al., 2017). The effects of rac-BHFF and 
ORM-27669 were compared in the presence of baclofen (30 µM) as the agonist (which alone 
produced a negligible signal over the baseline), and CGP-54626 (10-100 µM) as the 




Behavioral experiments  
Spontaneous locomotor activity 
These experiments were carried out both and at the University of Helsinki (Fig. 2A) and at 
Orion Pharma (Turku, Finland, presented in Figure S1). 
At the University of Helsinki, mouse locomotor activity was analyzed by video-
tracking software Ethovision XT (Version 10.1, Noldus Information Technology, Netherlands) 
for 90 min in polycarbonate 19 x 36 x 15 cm cages (Vashchinkina et al., 2012). The mice 
received different doses of GABAB PAMs or vehicle as a pretreatment (i.p.) 15 min before the 
animals received either saline or baclofen (1 mg/kg; i.p.) and were transferred into a novel 
cage for measurement of locomotor activity. Distances travelled during successive 15-min 
periods were calculated and compared between the treatments (Fig. 2A), and the first 30-min 
were pooled for the Fig. 2B.  
 
Conditioned place preference  
Biased place conditioning paradigm consisted of pre-conditioning, conditioning, and post-
conditioning phases (Cunningham et al., 2006; Vekovischeva et al., 2004). The pre-
conditioning phase consisted of a 15-min presentation to two distinct floor mats (a metal plate 
perforated with 1-cm holes and a plastic grid with 2-cm wide bars), bisecting a polycarbonate 
cage (19 x 36 cm) into two equal zones. Analysis of time that the mice spent on each floor 
mat revealed preferred and non- preferred floor mats. During conditioning phase, the entire 
cage floor was covered by two identical mats. Each daily session consisted of two 20-min 
trials, morning and evening trials. During morning sessions (8:00 - 10:00), mice were 
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pretreated with vehicle and 30 min later with saline and immediately placed on the preferred 
floor mats. During evening sessions (16:00 – 18:00), mice were pretreated i.p. with either 
GABAB PAMs or vehicle and 30 min later with saline, cocaine (10 mg/kg), or ethanol (0.5 
g/kg) and placed on the non-preferred floor mats. The daily conditioning procedure was 
repeated four times. The mats and cage were deodorized with 2% H2O2 after each animal. 
The injection-free post-conditioning test (15 min) was performed 48 h after the last 
conditioning session. During this test, the cage floor was equally covered with both floor mats 
used during conditioning. Locomotor activities and locations were determined by the 
Ethovision software. The difference (‘‘time shift’’) in time spent on the non-preferred material 
during pre-conditioning and post-conditioning tests was calculated as the measure of 
conditioned place preference (CPP). Two independent batches of mice were tested. 
 
Ethanol binge-like drinking  
We used the drinking-in-the-dark procedure (DID) adapted from Rhodes et al. (Rhodes et al., 
2005) facilitating stable limited-access ethanol drinking in mice. Different batches of mice 
were used for rac-BHFF and ORM-27669 tests. Three-hours into the dark cycle, a water 
bottle was replaced for 2 or 4 h with a 10-ml plastic tube affixed to a ball-bearing sipper and 
filled with 20% ethanol solution. During the first two weeks, the mice were given a 2-h access 
to 20% (v/v) ethanol for three consecutive days, and a 4-h access on the fourth day followed 
by a 3-day break; thereafter the mice had 4 h of access to ethanol for 4 days a week. After at 
least two weeks of drinking, the drug testing started. At this point, averaged basal 4-h drinking 
values were 4.1 ± 0.3 g/kg, n=13, and 4.2 ± 0.3 g/kg, n=16, (mean ± SEM) for mice used in 
the rac-BHFF and ORM-27669 experiments, respectively. During the following weeks, mice 
were pretreated with either GABAB PAMs or vehicle, and 30 min later given a 4-h ethanol 
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access. Treatment groups were arranged in a Latin square design. Mice had always an 
injection-free 4-h access to ethanol a day before testing the effects of vehicle or GABAB 
PAMs on ethanol intake. The DID paradigm was verified by pretreating mice with the opioid 
receptor antagonist naltrexone (10 mg/kg) that is known to reduce ethanol drinking (Hwa et 
al., 2014) (data not shown).  
 
Intravenous drug self-administration 
Drug self-administration (SA) procedure based on voluntary nose poking activity of mice was 
carried out as described in (Vashchinkina et al., 2012). Briefly, the custom-made apparatus 
(Ritec, Russia) consisted of four identical opaque plastic chambers (8 x 8 x 8 cm) for 
simultaneous testing of two pairs of mice. Each chamber was fitted with an infrared sensor 
and a nose poke hole (1.5 cm) on the frontal wall and a vertical slot (5 mm) at the bottom of 
the back wall for extending and fixing the tail. SA was determined in mouse pairs (active and 
yoked control) matched based on similarity of nose poke activity during 10-min pretests. 
Within 1 h after the pretest, matched pairs were pretreated (i.p.) with GABAB PAMs or vehicle. 
Thirty minutes later, the animal pairs were placed again into the chambers, and 27G needles 
connected to 1 ml syringes in a two-syringe infusion pump were inserted into the lateral tail 
vein of each mouse. During a 15-min test, each nose poke of the active mouse resulted in a 
simultaneous infusion (1.7 μl; 1 s duration) of cocaine (1 mg/ml) to both active and yoked 
mice. Each mouse was exposed for drugs only once. As a measure of reinforcement effect, R 
factor was calculated as the difference between the logarithm (log10) of the ratio between 
cumulative numbers of nose pokes by active and yoked mice during the SA session and the 




TH-EGFP mice were injected with either GABAB PAMs or vehicle and 15 min later with 
ethanol (2 g/kg), cocaine (10 mg/kg) or vehicle, and decapitated 24 h later. Horizontal 225-
μm-thick midbrain slices were prepared and preincubated as described previously 
(Vashchinkina et al., 2012). VTA DA neurons were visualized using fluorescence microscope 
(Olympus BX51WI, Hamburg, Germany), and whole-cell voltage-clamp recordings were 
performed with a Multiclamp 700A amplifier (Molecular Devices, Sunnyvale, CA, USA) 
(Vashchinkina et al., 2012). The currents were low-pass filtered at 1.6 kHz, and digitized at 
20 kHz (Molecular Devices). Electrodes (3-4 MΩ) contained (in mM, pH adjusted to 7.2-7.25 
and osmolarity to 280 mOsm): 130 cesium methanesulfonate, 10 HEPES, 0.5 EGTA, 8 NaCl, 
5 QX314, 4 MgATP, 0.3 MgGTP, and 10 BAPTA. α-Amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid (AMPA) and N-methyl-D-aspartate (NMDA) receptor-mediated excitatory 
postsynaptic currents (EPSCs) were induced by stimulating glutamatergic afferents at 0.1 Hz 
frequency using a bipolar stimulus electrode (Vashchinkina et al., 2012). Neurons were 
clamped at +40 mV under blockade of GABAA receptors (picrotoxin, 100 μM), and EPSCs 
were recorded for 10 min before and after the application of the NMDA receptor blocker D-(-)-
2-amino-5-phosphonopentanoic acid (AP5, 50 μM). The ratio was calculated by dividing the 
peak amplitude of AMPA receptor current with that of NMDA receptor current, averaged from 
30 EPSCs. To examine whether NMDAR function was altered after the treatment, we 
examined kinetics of NMDAR EPSCs (Monyer et al., 1992). The weighted decay time 
constant (tau, tW) of the NMDAR EPSCs at +40 mV was calculated by fitting a double 
exponential function to each average EPSC and using the following formula tW = [(A1xt1)+( 
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A2xt2)]/(A1+A2); where A1 and A2 are the amplitudes and t1 and t2 are the decay time 
constants of the fast and slow components, respectively (Barth and Malenka, 2001).  
 
Drugs 
Both rac-BHFF and ORM-27669 (provided by Orion Pharma, Espoo, Finland) were dissolved 
in 40% (v/v) polyethylene glycol/10% (v/v) polyoxyl-15-hydroxystearate (Solutol HS15) and 
diluted by one-half with 2% d-a-tocopheryl polyethylene glycol 1000 succinate (TPGS, w/v), in 
saline, and used for i.g. or s.c. (spontaneous locomotor study at Orion Pharma) or i.p. 
injections (all other in vivo studies) within 20 min of preparation (all from Tocris Bioscience, 
Bristol, UK). ORM-27669 was synthesized using the protocols that are described in the 
Supporting Information Methods. Preliminary pharmacokinetics of ORM-27669 in adult male 
Wistar rats suggested an elimination t½ of about 2.7 h and an AUCbrain/AUCplasma of about 0.6 
(Supporting Information Table S1). Baclofen and CGP-54626 (Tocris Bioscience), cocaine 
hydrochloride (Sigma-Aldrich, St. Louis, USA ) and ethanol (Altia Oyj, Rajamäki, Finland) 
were dissolved in saline for i.p. and i.v. injections. Ethanol solutions for the DID were made 
into tap water (20% v/v). For in vitro pharmacology studies, 10 mM stock solutions in DMSO 
(ORM-27669 and rac-BHFF) and water (baclofen, GABA and CGP-54626) were used.  
 
Statistical analyses 
The results are presented as means ± SEM. Data were statistically analyzed with the IBM 
SPSS Statistics 21 software (IBM, Armonk, New York, NY, USA) or Prism 6 (GraphPad 
Software, La Jolla, CA, USA), using ANOVA followed by a Bonferroni or Dunnett test (P < 





GABAB pharmacology and positive allosteric modulation of rac-BHFF and ORM-27669 
In the calcium-based assay, baclofen was found to be a full agonist with EC50 values of 1.9 ± 
0.4 and 0.80 ± 0.2 µM at human (n = 6) and rat (n = 7) GABAB receptors, respectively, 
similarly to GABA (1.0 ± 0.1 and 0.66 ± 0.08 µM, respectively). Rac-BHFF showed low 
efficacy and potency as an agonist at human and rat GABAB receptors (EC50 > 30 µM, data 
not shown), while ORM-27669 was similar to rac-BHFF at human receptors, but showed a 
weak partial agonism at rat receptors (EC50 9.8 ± 0.6 µM, intrinsic activity IA 0.26). ORM-
27669 was a less potent PAM compared to rac-BHFF, the difference in potency being slightly 
more prominent with baclofen than GABA as the agonist (Table 1). At 10 µM concentration, 
rac-BHFF was more efficient than ORM-27669 in potentiating the GABA and baclofen dose-
responses at human and rat GABAB receptors (fold changes in Table 1). ORM-27669 
potentiated the maximal efficacy to a greater extent than rac-BHFF. Rac-BHFF induced a 
20% reduction of maximal efficacy of both GABA and baclofen at the rat GABAB receptors 
(Table 1).  
In the [35S]GTPγS binding assay, GABA increased membrane association of 
[35S]GTPγS with EC50 values of 0.73 ± 0.08 and 2.2 ± 0.1 µM, at human and rat receptors, 
respectively (Table 1B). Rac-BHFF (10 µM) was also an agonist, with a slightly lower efficacy 
(0.92 ± 0.04) as compared to 100 µM GABA, which prevented accurate estimation of its 
allosteric pharmacology in this assay (Table 1B). ORM-27669 showed positive allosteric 
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effect by potentiating GABA dose-response, i.e., shifting the GABA dose-response to the left, 
by about 2.5-fold, at human and rat receptors.  
Taken together, ORM-27669 was found to be a less potent and efficient GABAB 
PAM than rac-BHFF at both human and rat GABAB receptors. Some differences in the in vitro 
pharmacological profile were found at rat GABAB receptors between the compounds and the 
signaling pathways studied. Rac-BHFF was a pure PAM in the calcium-based assay and an 
intrinsic agonist and PAM in the endogenous signaling [35S]GTPγS binding assay. ORM-
27669 showed a similar allosteric profile in both signaling assays, with some tendency to a 
weak partial agonism at rat GABAB receptors.  
Next, we aimed to find out how brain regional stimulation of [35S]GTPγS binding 
would be affected by the PAMs (Fig. 1BC). Both Rac-BHFF (10 µM) and ORM-27669 (300 
µM) potentiated the stimulation of binding of [35S]GTPγS by a low concentration of baclofen 
(30 µM) in GABAB receptor antagonist-sensitive manner widely in mouse brain regions (Fig. 
1B; similar data were found also for Wistar rat brain sections, data not shown). Baclofen alone 
at this low concentration and both PAMs alone had no effects. While the combined effect was 
clearly greater with rac-BHFF, the regional profiles were very similar for both PAMs, 
suggesting that they activated the same population(s) of baclofen-stimulated GABAB receptor 
subtypes (Fig. 1C). It should be noted that our [35S]GTPγS binding assay was not sensitive 
enough for consistent quantification of the GABAB receptor activation in the VTA. 
Specificity of ORM-27669 was screened in tissue homogenates or recombinant 
preparations using orthosteric sites of 121 relevant targets at Eurofins Cerep SA (Celle-
Levescault, France). At 10 µM concentration, no affinity was detected to any of the targets 
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studied (defined by <50 % inhibition of specific binding), except for affinity to human PACAP 
(PAC1) receptor (52% inhibition, Supporting Information Table S2). Rac-BHFF at 10 µM has 
also been found to be very selective, as out of the 56 targets tested (Malherbe et al., 2008), 
only ligand binding to the CCK1 receptor was inhibited by almost 90%.  
 
Effects of GABAB receptor ligands on locomotor activity of mice 
In initial experiments at Orion Pharma with acute administration of baclofen, rac-BHFF and 
ORM-27669, we tested several doses to find out whether the compounds induced changes in 
spontaneous locomotor activity counts in mice. When tested separately against the common 
vehicle-treated group, the data showed that only baclofen at the doses of 10 and 30 mg/kg 
(F4,33 = 11.4, p < 0.0001), and not rac-BHFF (F4,30 = 1.4, p > 0.26), reduced the activity (Fig. 
S1: for both drugs, treatment effect F8,56 = 5.7, p < 0.0001), in agreement with (Besheer et al., 
2004). ORM-27669 did not affect locomotion within a wide dose range (F4,35 = 1.4, p > 0.25). 
Then, we re-tested non-sedative doses of rac-BHFF and ORM-27669 after acute 
i.p. injections in mice at the University of Helsinki and found that rac-BHFF at 30 mg/kg and 
ORM-27669 at 100 mg/kg did not significantly alter the distances traveled (Fig. 2AB), but rac-
BHFF at 60 mg/kg did reduce the locomotion (Fig. 2B). Baclofen (1 mg/kg) alone did not alter 
locomotor activity as compared to vehicle treatment, but when co-administered with rac-BHFF 
(30 mg/kg) and ORM-27669 (100 mg/kg) a clear decrease in locomotor activity was induced 
(Fig. 2AB, treatment effect for rac-BHFF: F5,52 = 7.4, p < 0.001; for ORM-27669:  F5,69 = 4.6, p 
= 0.001). The locomotion-reducing effect of rac-BHFF at 60 mg/kg was no more enhanced by 
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baclofen. Higher doses of baclofen were not included in further behavioral experiments due to 
its sedative effect.  
 
Single in vivo doses of GABAB receptor ligands failed to induce long-lasting 
potentiation in the VTA DA neurons  
In VTA DA neurons of midbrain slices from baclofen-, rac-BHFF- and ORM-27669-treated 
mice obtained 24 h after the single injections, the AMPA and NMDA receptor-mediated 
EPSCs and their current ratios were similar to those in neurons from vehicle-treated mice 
(Fig. 2CD; one-way ANOVA F7,55 = 0.70, p = 0.62). Co-administration of baclofen (1 mg/kg) 
with rac-BHFF (30 mg/kg) and ORM-27669 (10 mg/kg) also failed to increase the 
AMPA/NMDA ratio (Fig. 2D; F5,45 = 1.9, p = 0.1).  
In addition to amplitude analysis of the EPSCs, we also examined the kinetics of 
NMDA EPSCs to estimate whether the treatments induced any differences in NMDAR subunit 
composition (Barth and Malenka, 2001; Flint et al., 1997). We found no difference in the 
weighted decay time constants (τW) of the NMDA EPSCs from drug-treated mice compared 
to the decay time constants of neurons from vehicle-treated mice [F9,73 = 0.77, p = 0.64; tW 
given as mean ± SEM in ms: vehicle 71 ± 19;  baclofen (1 mg/kg) 68 ± 9; baclofen (5 mg/kg) 
77 ± 17; baclofen (30 mg/kg) 103 ± 50; rac-BHFF (30 mg/kg) 114 ± 24; rac-BHFF (100 mg/kg) 
77 ± 9; baclofen (1 mg/kg) + rac-BHFF (30 mg/kg) 105 ± 20; ORM-27669 (10 mg/kg) 66 ± 9; 
ORM-27669 (100 mg/kg) 63 ± 5; baclofen (1 mg/kg) + ORM-27669 (10 mg/kg) 96 ± 18].  
 
Comparison of pretreatment effects of baclofen and GABAB PAMs on drug-induced 
plasticity in VTA DA neurons 
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We next determined whether the pretreatment with baclofen (1-30 mg/kg), rac-BHFF (30-100 
mg/kg) and ORM-27669 (100 mg/kg) affected ethanol- and cocaine-induced increase in 
AMPA/NMDA ratio (Ungless et al., 2001; Vashchinkina et al., 2012). In this set of 
experiments, we recorded distinct subpopulations of VTA DA neurons, i.e., those in the 
dorsomedial posterior VTA in ethanol-treated mice (Mrejeru et al., 2015) and those in the 
ventrolateral VTA in the cocaine-treated mice (Lammel et al., 2011). Consistent with previous 
results, ethanol (2 g/kg, i.p.) and cocaine (10 mg/kg, i.p.) increased AMPA/NMDA ratios 
compared to vehicle (Fig. 3AB).  
Ethanol-induced increase in the AMPA/NMDA ratio in the VTA DA neurons was 
suppressed by all types of pretreatments (except for the low dose of baclofen) given 15 min 
before the single ethanol dose (Fig. 3A, F6,48 = 7.4, p ˂ 0.0001). Both pretreatments with rac-
BHFF (30 mg/kg) and ORM-27669 (100 mg/kg) effectively reversed ethanol-induced 
AMPA/NMDA ratio at the non-sedative dose, whereas pretreatment with baclofen was 
effective only at higher sedative dose (30 mg/kg) compared to vehicle-treated mice. 
Cocaine-induced increase in the AMPA/NMDA ratio in the VTA DA neurons was 
suppressed only by pretreatment with rac-BHFF given 15 min before the single cocaine dose 
(Fig. 3B, F4,37 = 5.2, p = 0.002). Particularly, pretreatment with a non-sedative dose of rac-
BHFF (30 mg/kg) markedly reversed cocaine-induced AMPA/NMDA ratio, but pretreatments 
with baclofen (1 mg/kg) and ORM-27669 (100 mg/kg) were not effective compared to vehicle-
treated mice. Thus, rac-BHFF effectively reversed both ethanol- and cocaine-induced 
neuroplasticity, whereas ORM-27669 seemed to be more potent in reversing ethanol- than 
cocaine-induced neuroplasticity. 
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In some mice, the highest dose of rac-BHFF (100 mg/kg) used alone (n = 3 out of 
10 mice) or in combination with ethanol (n = 1 out of 8) or cocaine (n = 1 out of 7) induced a 
deep sedative state documented even at 24 h after the treatment. These mice were sacrificed 
and excluded from the study.  
 
Pretreatment with non-sedative doses of rac-BHFF and ORM-27669 suppressed 
reward-related behaviors in mice 
We then tested whether the non-sedative doses of rac-BHFF (3-30 mg/kg) and ORM-27669 
(100 mg/kg), that counteracted the drug-induced neuroplasticity, also altered the reinforcing 
properties of ethanol and cocaine. First, we studied the effects of pretreatments with the 
GABAB PAMs on the development of the CPP to ethanol and cocaine. In line with previous 
results (Vekovischeva et al., 2004), within the vehicle-pretreated mice, ethanol- and cocaine-
conditioned mice developed the CPP compared to the saline-conditioned mice (Fig. 4A, F6,75 
= 7.9, p ˂ 0.0001). When conditioning to ethanol was carried out after pretreatments with 
either PAM, no statistically significant CPP was expressed as compared to vehicle 
pretreatment (Fig. 4A; p ˃ 0.05 by Bonferroni test), suggesting that the rewarding effects of 
ethanol were diminished by the PAMs. In contrast, only pretreatment with rac-BHFF, but not 
with ORM-27669, suppressed expression of cocaine-induced CPP (Fig. 4A). Additional 
analysis of locomotor activity during the conditioning sessions suggested that only rac-BHFF 
slightly suppressed cocaine-induced locomotor hyperactivity during the 3rd conditioning 
session (Fig. 4B: F4,53 = 42.1, p ˂ 0.05 for cocaine vs. rac-BHFF + cocaine).  
Then, we studied the effect of pretreatments with the GABAB PAMs on ethanol 
drinking and self-administration of cocaine. Using the DID paradigm, we found that ethanol 
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intake was significantly attenuated by pretreatments with both rac-BHFF (30 mg/kg; p ˂ 0.05) 
and ORM-27669 (100 mg/kg, p ˂ 0.001) as compared to ethanol intake after vehicle 
injections (Fig. 4D). In contrast, acute intravenous self-administration of cocaine was 
suppressed selectively by rac-BHFF (30 mg/kg: F2,24 = 4.8, p ˂ 0.05) in a dose-dependent 
manner, but not at all by ORM-27669 (100 mg/kg) (Fig. 4E: F2,13 = 13.3, p ˂ 0.01). Taken 
together, rewarding effects of ethanol were blunted by both rac-BHFF and ORM-27669, while 
only rac-BHFF affected the rewarding effects of cocaine. 
 
DISCUSSION 
The present results demonstrate for the first time that GABAB receptor agonists are able to 
reverse persistent neuroadaptations induced by drugs of abuse in the VTA DA neurons. 
Prominent suppression of alcohol- and cocaine-induced synaptic plasticity in mice was 
observed with two different GABAB PAMs, a potent and highly efficient benzofuranone rac-
BHFF and a novel low-potency and low-efficacy non-benzofuranone compound ORM-27669. 
The effect was comparable to that observed with a sedative dose of the orthosteric agonist 
baclofen. Furthermore, the non-sedative doses of GABAB PAMs clearly decreased voluntary 
drinking of ethanol in mice, while only the more efficient and potent compound reduced acute 
intravenous self-administration of cocaine. Ethanol- and cocaine-induced place preference 
was not consistently affected by GABAB PAMs, although the results suggested that ethanol 
reward was somewhat sensitive to both PAMs, while cocaine reward again only to rac-BHFF. 
The lack of sedation during the behavioral tests suggests that GABAB PAMs may have a 
wider therapeutic window than baclofen, although we found that in some animals that the 
administration of the highest dose (100 mg/kg) of the potent rac-BHFF induced prolonged, 
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heavy sedation.  
 
VTA neuroadaptations  
Data obtained from measurements of the AMPA and NMDA receptor currents in VTA DA 
neurons from juvenile mice demonstrated that in vivo administration of baclofen and PAMs 
alone did not have long-term neuroplasticity effects on DA neurons. Moreover, there were no 
alterations in the kinetics of NMDA receptor currents, indicating that they did not alter the 
subunit composition of the receptors (Barth and Malenka, 2001; Brothwell et al., 2008). In 
line, using c-Fos and DFosB expression to estimate neuronal activation, (Lhuillier et al., 2007) 
demonstrated that neither baclofen nor a PAM GS39783 per se altered expression of these 
immediate early genes in the striatum. 
Both baclofen and GS39783 potently reduced cocaine-induced c-Fos expression 
in the striatum (Lhuillier et al., 2007). However, GS39783 blocked the prolonged DFosB 
expression by subchronic cocaine efficiently in the dorsal striatum, but not in the nucleus 
accumbens, indicating regional selectivity in its actions. In order to compare the pretreatment 
effects of distinct GABAB receptor ligands on plasticity induced by addictive substances, we 
examined comparable non-sedative doses of rac-BHFF, ORM-27669 and baclofen. We 
recorded distinct VTA DA neuron subgroups due to well-known regional differences in their 
responses to alcohol and cocaine. Particularly, VTA DA neurons from the dorsomedial 
posterior VTA have been found to be highly responsive to alcohol (Mrejeru et al., 2015), while 
VTA DA neurons located in the ventrolateral VTA are highly responsive to cocaine (Lammel 
et al., 2011). Standard neuroplasticity-inducing single doses of ethanol (2 g/kg) and cocaine 
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(10 mg/kg) produced significantly increased AMPA/NMDA receptor current ratios in the DA 
neurons of the respective regions of the VTA (Fig. 3). At non-sedative doses, rac-BHFF, but 
not ORM-27669, suppressed cocaine-induced plasticity. The magnitude of the effect 
produced by rac-BHFF was comparable to baclofen at 30 mg/kg, a dose known to induce 
profound sedation (Besheer et al., 2004). On the other hand, ethanol effects were suppressed 
to the same extent by both rac-BHFF and ORM-27669.  
Our present and the earlier findings (Lhuillier et al., 2007) indicate that the 
GABAB PAMs have the potential to counteract at least some processes of the 
neuroplasticity/adaptation to drugs of abuse. Further characterization of the binding sites and 
signaling pathways for the PAMs is thus warranted in order to interpret their differences in 
modulating VTA neuroplasticity responses to ethanol and cocaine. Our autoradiographic 
analyses on mouse brain sections anyway indicate a robust difference in the potency and 
efficacy between rac-BHFF and ORM-27669, but identical brain regional GABAB receptor 
populations as targets (Fig. 1BC). Therefore, it is plausible that ethanol-induced 
neuroadaptation is less stringent than cocaine neuroadaptation, being sensitive to lower 
stimulation of GABAB receptors. It should be noted that, as discussed above, different VTA 
DA neuron populations are sensitive to ethanol and cocaine and only the sensitive ones were 
recorded here. Therefore, it was not surprising that the two PAMs had different effects. It 
should be also noted that the poorly soluble ORM-27669 was used in behavioral experiments 
at its maximal dose, which still appeared to potentiate the low-dose baclofen effect on 
locomotion, similarly to rac-BHFF (30 mg/kg, Fig. 2AB). 
 
Behavioral characterization of GABAB PAMs 
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Dose-dependent hypoactivity was observed in mice with baclofen (Figure S1) and in one 
experiment with rac-BHFF (Fig. 2A, but not in Figure S1), while ORM-27669 consistently 
induced no hypoactivity. Co-administration of subthreshold sedative doses of baclofen and 
GABAB PAMs resulted in marked enhancement of sedation (Fig. 2AB), confirming that such 
effects of PAMs are mediated by GABAB receptor (Filip et al., 2015). 
Doses of GABAB PAMs that were efficacious in neuroplasticity experiments in 
juvenile mice were used in adult mice in reward-related behavioral paradigms, which were 
previously linked to VTA adaptations (Dunn et al., 2005; Harris et al., 2004). Rac-BHFF 
suppressed neuroplasticity and attenuated behavioral responses to cocaine and ethanol, 
suggesting correlated mechanisms (Figs 3 and 4). Pretreatment with rac-BHFF did not 
consistently affect cocaine-induced hyperactivity during the conditioning sessions. However, 
in the present experiments, cocaine did not induce locomotor sensitization after repeated 
conditioning doses, and thus the effects of GABAB PAMs on sensitization could not be 
assessed. The GABAB PAM GS39783 efficiently blocks cocaine-induced hyperactivity, but 
affects only slightly the sensitization to cocaine (Lhuillier et al., 2007). Pretreatment with rac-
BHFF reduced ethanol drinking, in line with (Maccioni et al., 2010), and it also reduced acute 
cocaine self-administration. ORM-27669 effectively reduced only ethanol drinking, but not 
cocaine self-administration and cocaine-induced hyperlocomotion (Fig. 4). These results are 
in agreement with the effects on VTA DA neuroplasticity, as ORM-27669 also failed to 
reverse cocaine-induced neuroplasticity (Fig. 3). 
Only modest effects were seen in the CPP test by the pretreatments with the 
GABAB PAMs. Conditioning with ethanol and cocaine induced significant CPP, and these 
effects were reduced by the GABAB PAMs to the level that statistically significant CPPs were 
 23 
no more detectable. However, the time shifts during preference testing in mice with 
conditioning pretreatments with rac-BHFF and ORM-27669 did not differ from the 
corresponding vehicle-pretreated groups. The small suppression of development of ethanol- 
and cocaine-induced CPP by rac-BHFF and ORM-27669 might be attributed to their inability 
to also act on brain areas such as the extended amygdala and olfactory tubercle that also 
regulate conditioned effects of cues associated with cocaine (Tzschentke, 2007) and ethanol 
(Gremel and Cunningham, 2008) and/or to affect conditioned motivational properties of drug-
paired cues. To our knowledge, no study has reported clear effects of rac-BHFF on 
development or expression of CPP induced by addictive compounds in mice (Filip et al., 
2015). Furthermore, there is no evidence for rac-BHFF per se to induce conditioned place 
preference or aversion (Filip et al., 2015). Conditioning with baclofen also fails to induce place 
preference or aversion (reviewed in (Tzschentke, 2007)), nor does co-treatment with it block 
ethanol-induced place preference in mice (Chester and Cunningham, 1999). Thus, the CPP 
test may not be the proper test to reveal any robust anti-addiction effects of GABAB receptor 
ligands. 
 
In vitro GABAB receptor pharmacology 
Human and rat GABAB receptors utilized here responded rather similarly to agonists and 
PAMs in both intracellular Ca2+ mobilization and G protein-coupling assays, and with the 
GABAB subunits being conserved in mouse (Bettler et al., 2004), the data suggest high 
translational potential of studied GABAB PAMs. Rac-BHFF was found to be a pure allosteric 
modulator in the intracellular Ca2+ mobilization assay, whereas in the [35S]GTPγS binding 
assay the compound demonstrated agonistic activity at both human and rat GABAB receptors. 
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Earlier Malherbe et al. (Malherbe et al., 2008) also reported agonistic activity of rac-BHFF in 
the absence of exogenous GABA in the stable CHO-Gα16-hGABAB(1a,2a) cell system. It still 
remains unclear whether rac-BHFF per se is able to directly activate native GABAB receptors, 
and whether the allosteric profile differs depending on the signalling pathway studied 
(calcium-based vs. [35S]GTPγS assay) and/or the level of constitutive activity of receptors in 
the system studied.  
In contrast to rac-BHFF, ORM-27669 had a more pure allosteric pharmacological 
profile in both assays but with a tendency to increased partial agonistic profile at rat compared 
to human GABAB receptors. The limited buffer-solubility of ORM-27669 and rac-BHFF might 
underestimate the actual in vitro potency, with the lipophilicity being often a characteristic of 
GABAB receptor ligands (Urwyler, 2011). 
Despite the differences in potency and allosteric profile between the GABAB 
PAMs, the mouse brain regional profiles were very similar for the PAMs, suggesting that they 
activate the same population(s) of GABAB receptor subtypes. ORM-27669 did not display 
specific affinity to 121 receptors and binding sites studied at 10 µM concentration, indicating 
selective targeting to GABAB receptors (Supporting Information Table S2). 
 
Mechanism of suppression of drug-induced neuroplasticity in VTA DA by GABAB 
ligands  
Suppression of drug-induced neuroplasticity and reward-associated behaviour by GABAB 
agonists and PAMs may result from the restoration of inhibition, which may be disturbed by 
drugs of abuse (Liu et al., 2005; Nugent et al., 2007). In the VTA, there are several putative 
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targets for GABAB ligands, including postsynaptic GABAB receptors on DA neurons (Cruz et 
al., 2004; Lalive et al., 2014; Munoz et al., 2016) or/and presynaptic GABAB receptors on the 
afferent GABAergic projections (Padgett et al., 2012). Indeed, recent reports link both 
postsynaptic and presynaptic GABAB receptor mechanisms in the actions of ethanol and 
psychostimulants in VTA DA neurons. Both ethanol (Herman et al., 2015) and cocaine (Wise 
et al., 1995) induce bursting mode of firing in VTA DA neurons. It has been shown that the 
bursting mode, but not the tonic firing mode, potentiates GABAB-GIRK-mediated slow 
inhibitory postsynaptic currents (IPSCs) in VTA DA neurons (Lalive et al., 2014), which then 
brings the firing back to baseline. Thus, facilitation of GABAB receptors on VTA DA neurons 
by agonists and PAMs can lead to augmentation of GIRK-mediated inhibition that could 
reduce VTA DA neuron firing and DA efflux in the terminals (Herman et al., 2015). In the VTA, 
the reduction of DA neuron firing would limit the development of neuroplasticity, as detected 
when GABAB PAMs were given before single doses of ethanol or cocaine. 
Alternatively, suppression of drug-induced neuroadaptations in VTA DA neurons 
could be mediated via facilitation of presynaptic GABAB receptors. Psychostimulants 
persistently impair GABAB-GIRK slow IPSCs in VTA GABA neurons (Padgett et al., 2012) and 
DA neurons (Arora et al., 2011; Cruz et al., 2004; Munoz et al., 2016), via different 
mechanisms. Ethanol affects the excitatory/inhibitory balance by directly activating GIRK3 
channels in VTA DA neurons (Federici et al., 2009; Herman et al., 2015). Hence, activation of 
GABAB receptors in VTA GABA cells by their agonists or PAMs may restore 
excitatory/inhibitory balance previously disturbed by drugs of abuse.  
In the hippocampus, GABAB-GIRK slow IPSCs have been proposed to transmit 
only pertinent information to and within the hippocampus. Particularly, GABAB-GIRK slow 
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IPSCs appear only after high-frequency stimulation and, at least in part, prevent the 
development of LTP (Hasuo and Akasu, 2001). If the same holds true for the VTA, then the 
use-dependent activation of GABAB receptors (seen as the absence of the VTA plasticity after 
GABAB PAMs) implies that GABAB receptors act as a protective regulatory gate to prevent 
drug-induced overflow of information from the VTA to its targets, including the nucleus 
accumbens. 
In conclusion, the present study demonstrated that use-dependent activation of 
GABAB receptors can decrease long-term adaptive synaptic changes in VTA DA neurons and 
reward-associated behaviour after ethanol and cocaine treatments. Importantly, efficacy of 
GABAB PAMs in our models was observed at non-sedative doses that were devoid of their 
own effects on VTA plasticity, consistent with the therapeutic principle of PAMs. It should be 
noted that only ethanol effects could be reversed also by the low-efficacy GABAB PAM ORM-
27669, while the high-efficacy ligand rac-BHFF reversed both ethanol and cocaine effects.  
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Positive allosteric modulation pharmacology of rac-BHFF and ORM-27669 at human and rat 
GABAB receptors in the calcium-based and [35S]GTPγS binding assay. A. In the calcium-
based assay, rac-BHFF and ORM-27669 showed similar allosteric pharmacology in PAM 
EC50 values (in µM) in the presence of EC5-EC11 concentration of GABA or baclofen and in 
potentiation (at 10 µM) of the GABA and baclofen dose-response curves at both human and 
rat GABAB receptors. Potentiation was determined as a leftward shift of GABA and baclofen 
dose-response curves (fold potentiation of agonist EC50 values). B. Rac-BHFF showed 
significant intrinsic agonism (IA, relative to 100 µM GABA ± SEM), which prevented accurate 
estimation of its allosteric pharmacology. ORM-27669 (at 10 µM concentration) showed 
potentiation of GABA dose-response at both human and rat GABAB receptors. Results are 




PAM EC50 (µM) 
GABA as agonist 
PAM EC50 (µM) 
baclofen as agonist 
Potentiation at 10 µM 
with GABA 
as agonist (fold / Emax) 
Potentiation at 10 µM 
with baclofen as 
agonist (fold / Emax) 
human GABAB receptors 
Rac-BHFF 2.3 ± 0.1 3.1 ± 0.4 13.8 ± 2.6 / 1.1 ± 0.1 16.3 ± 3.3 / 1.1 ± 0.1 
ORM-27669 5.3 ± 0.5 10.9 ± 1.8 7.8 ± 1.3 / 1.2 ± 0.1 4.8 ± 0.5 / 1.2 ± 0.1 
rat GABAB receptors 
Rac-BHFF 1.0 ± 0.4 0.6 ± 0.1 14.6 ± 1.4 / 0.8 ± 0.1 8.7 ± 1.7 / 0.8 ± 0.1 
ORM-27669 1.9 ± 0.2 2.9 ± 0.2 3.7 ± 1.2 / 1.0 ± 0.1 5.3 ± 0.7 / 1.1 ± 0.1 
B 
Fold change of 
potentiation of       
GABA EC50 
Fold change of 
potentiation of          
100 µM GABA  
Agonism (IA) as compared 
to 100 µM GABA 
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human GABAB receptors 
Rac-BHFF N/A 0.90 ± 0.02 0.92 ± 0.04 
ORM-27669 2.5 ± 0.2 1.00 ± 0.02 0.06 ± 0.02 
rat GABAB receptors 
Rac-BHFF  N/A  1.57 ± 0.09 0.54 ± 0.06 








Figure 1  A. Chemical structures of test compounds. B. Representative images of the 
stimulation of [35S]GTPgS binding in adult mouse brains by baclofen, rac-BHFF and ORM-
27669. The [35S]GTPgS binding in the presence of 30-μM baclofen and its robust potentiation 
by 300-μM ORM-27669 and 10-μM rac-BHFF, respectively, in many brain regions. The 
effects of both PAMs were fully antagonized in the presence of GABAB receptor antagonist 
CGP-54626 (10 μM). C. Quantitative data on the stimulation of G protein coupling by rac-
BHFF and ORM-27669 at 10 and 300 μM concentrations, respectively, in the presence of 30 
µM baclofen, which was almost inactive alone at this concentration. Data are means ± SEM, n 
= 5 brains. (CbMol, cerebellar molecular layer; CbGr, cerebellar granule cell layer; Ctx, 
cerebral cortex; SuG, superior colliculus; NAc, nucleus accumbens; CPu-DL, dorsolateral 
caudate-putamen; Th-MG, thalamic medial geniculate nucleus; CA3, hippocampal CA3 area; 
CA1, hippocampal CA1 area; DG, hippocampal dentate gyrus).  
 
Figure 2  Effects of single i.p. administrations of GABAB receptor ligands and their co-
administration on spontaneous locomotor activity in C57BL/6J mice, and on AMPA/NMDA 
receptor current ratios in VTA DA neurons of midbrain slices obtained ex vivo 24 h after the 
drug injection in TH-EGFP mice. A. Time course of the effects of GABAB drugs during the 90-
min measuring period for 15-min time bins. Acute i.p. administration of rac-BHFF and ORM-
27669 was tested in two separate experiments in adult C57BL/6J mice. On the left, results for 
mice injected with Veh (n = 8), Bac1 (n = 9), BH30 (n = 5), BH60 (n = 10), co-administration of 
baclofen and rac-BHFF (BH30+Bac1, n = 8; BH60+Bac1, n = 14). On the right, the results 
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from the ORM-27669 test: Veh (n = 17), Bac1 (n = 12), ORM10 (n = 11), ORM30 (n = 11), 
ORM100 (n = 12), co-administration ORM-27669 with baclofen (ORM100+Bac1, n = 12). 
Data are presented as mean distance traveled + SEM (unless within the symbol). * p < 0.05, 
**p < 0.01 for the significance of difference from the vehicle group (ANOVA followed by 
Bonferroni test). B. Cumulative distances traveled during 30 min after the drug 
administrations. Data are presented as mean distance traveled + SEM. * p < 0.05, **p < 0.01, 
***p < 0.001 for the significance of difference from the vehicle group. C. Representative 
examples of AMPA and NMDA receptor-mediated current traces for midbrain slices from mice 
injected 24 h earlier with vehicle, baclofen, ORM-27669 and rac-BHFF. Calibration: 20 pA/50 
ms. D. AMPA/NMDA (A/N) receptor current ratios for vehicle (Veh, n = 14, where n is the 
number of tested mice), Bac1, 1 mg/kg, n = 8; Bac5, 5 mg/kg, n = 7; Bac30, 30 mg/kg, n = 7; 
BH30, 30 mg/kg, n = 7; BH100, 100 mg/kg, n = 7; BH30+Bac1, n = 9; ORM10, 10 mg/kg, n = 
8; ORM100, 100 mg/kg, n = 7; and ORM10+Bac1, n = 4, are shown as means + SEM. No 
statistically significant differences between the groups (F9,66 = 0.6, p = 0.7). 
 
Figure 3  Effects of GABAB ligands on ethanol- and cocaine-induced neuroplasticity. The 
AMPA/NMDA receptor current ratio (A/N ratio) in VTA DA neurons of midbrain slices obtained 
ex vivo 24 h after the drug injection in TH-EGFP mice. A. Treatment with vehicle (Veh, n = 8, 
where n is the number of tested mice), ethanol (EtOH, 2 g/kg, n = 14), baclofen + ethanol 
(Bac1+EtOH, n = 7; Bac30+EtOH, n = 5), rac-BHFF + ethanol (BH30+EtOH, n = 7; 
BH100+EtOH, n = 8), ORM-27669 + ethanol (ORM100+EtOH, n = 6). B. Treatment with 
vehicle (Veh, n = 9), cocaine (coc, 10 mg/kg, n = 13), baclofen + cocaine (Bac1+Coc, n = 5), 
rac-BHFF + cocaine (BH30+Coc, n = 7) and ORM-27669 + cocaine (ORM100+Coc, n = 8). 
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Data are shown as mean + SEM. *p < 0.05, **p < 0.01, ***p < 0.001 for the significance of the 
difference from ethanol or cocaine group (one-way ANOVA followed by Dunnett test). 
 
Figure 4  Effects of 30-min pretreatment with rac-BHFF and ORM-27669 on ethanol- and 
cocaine-induced place conditioning and self-administration in adult C57BL/6J mice. A. CPP 
expressed as time shifts between post- and pre-conditioning times spent in the drug-paired 
compartment at 48 h after the last conditioning session with saline (Sal, n = 17), ethanol 
(EtOH, 0.5 g/kg, n = 9), rac-BHFF 30 mg/kg + EtOH (BH30+EtOH, n = 6), and ORM-27669 
100 mg/kg + EtOH (ORM100+EtOH, n = 12), cocaine (Coc, 10 mg/kg, n = 16), rac-BHFF + 
cocaine (BH30+Coc, n = 11), ORM-27669 + cocaine (ORM100+Coc, n = 11). Conditioning 
with ethanol and cocaine induced statistically significant CPP (*** p < 0.001), but not when the 
animals were pretreated with BH30. ORM100 only reduced conditioning to ethanol. B, C. 
Locomotor activity during 20-min conditioning sessions after pretreatments of vehicle, rac-
BHFF (B) or ORM-27669 (C). *p < 0.05, a significant reduction of cocaine-induced activity by 
BH30. D. Four-hour intake of ethanol (20%, v/v) after pretreatment with vehicle (Veh, n = 13) 
and rac-BHFF (BH30, n = 13) or with vehicle (Veh, n = 16) and ORM-27669 (ORM100, n = 
16). Data are means ± SEM. *p < 0.05, ***p<0.001 for the significance of the difference from 
vehicle group (Student t-test). E. Reinforcement factor for cocaine i.v. self-administration (SA) 
30 min after pretreatment with rac-BHFF and ORM-27669. Drug-naive C57BL/6J mice were 
allowed to i.v. self-administer saline (Veh+Sal, n = 4, where n is the number of tested pairs of 
active and yoked-control mice) or cocaine (Coc, 1 mg/ml) during 20-min sessions. On the left, 
the mice were pretreated with vehicle (Veh+Coc, n = 3) or ORM-27669 (100 mg/kg, 
ORM100+Coc, n = 9), and, on the right, with vehicle (Veh+Coc, n = 13) or rac-BHFF (3 mg/kg 
BH3+coc, n = 6; 30 mg/kg BH30+Coc, n = 8). A positive reinforcement factor indicates 
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positive reinforcement. Data are means ± SEM. **p<0.01, ***p<0.001 for the significance of 
the differences from vehicle-saline group, *p < 0.05 for the significance of the difference from 
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